Form
SCHEDULE 13G
Passive or exempt beneficial ownership filing.
ARCH Venture Fund X, L.P. - 31 Mar 2025 SCHEDULE 13G Report for Maze Therapeutics, Inc. Common Stock par value $0.0001 per share (MAZE)
- Filing manager
- ARCH Venture Fund X, L.P.
- Reporting owner
- ARCH Venture Fund X, L.P.
- Beneficially owned shares
- 4,120,053 shares
- Large-stake signal
-
Ownership
9.4%Beneficial ownership of this reported class.
Shares
4,120,053 sharesShares beneficially owned as disclosed.
Event date
31 Mar 2025Date tied to the ownership event or amendment.
Accepted by SEC
15 May 2025EDGAR acceptance date.
How to read this large-stake filing
- Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
- Compare this filing with the holder history and issuer page before treating the percentage as a current position.
- Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
- Class ownership
- 9.4%
- Symbol
- MAZE
- Shares outstanding
- 43,830,351 shares
- SEC form
- SCHEDULE 13G
- Accepted by SEC
- 15 May 2025, 17:05:19 UTC
- Event date
- 31 Mar 2025
- Source filing
- View source filing
Ownership signal
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Subject security
Names, identifiers, and filing context for this profile.
2 source fields
Source evidence
Original filing metadata and source links for verification.
4 source fields
Key filing fact
ARCH Venture Fund X, L.P. disclosed 9.4% ownership in Maze Therapeutics, Inc. Common Stock par value $0.0001 per share (MAZE) on 31 Mar 2025.
Key facts
- ARCH Venture Fund X, L.P. filed SCHEDULE 13G for Maze Therapeutics, Inc. Common Stock par value $0.0001 per share (MAZE).
- Disclosed ownership: 9.4%.
- Date of event: 31 Mar 2025.
Change
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 15 May 2025, 17:05.
Research use
- This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
- Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.
Evidence
Backed by Schedule 13D/13G
View source filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Disclosed reporting parties (9)
Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares owned | Sole voting power | Shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| ARCH Venture Fund X, L.P. | 9.4% | 4,120,053 | 0 | 4,120,053 | ARCH Venture Partners X, L.P. | its General Partner | |
| ARCH Venture Fund X Overage, L.P. | 9.4% | 4,120,053 | 0 | 4,120,053 | ARCH Venture Partners X Overage, L.P. | its General Partner | |
| ARCH Venture Partners X, L.P. | 9.4% | 4,120,053 | 0 | 4,120,053 | ARCH Venture Partners X, LLC | its General Partner | |
| ARCH Venture Partners X Overage, L.P. | 9.4% | 4,120,053 | 0 | 4,120,053 | ARCH Venture Partners X, LLC | its General Partner | |
| ARCH Venture Partners X, LLC | 9.4% | 4,120,053 | 0 | 4,120,053 | /s/ Mark McDonnell | * Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director | |
| Keith Crandell | 9.4% | 4,120,053 | 0 | 4,120,053 | /s/ Mark McDonnell | * Mark McDonnell, as Attorney-in-Fact for Keith Crandell | |
| Kristina Burow | 9.4% | 4,120,053 | 0 | 4,120,053 | /s/ Mark McDonnell | * Mark McDonnell, as Attorney-in-Fact for Kristina Burow | |
| Steven Gillis | 9.4% | 4,120,053 | 0 | 4,120,053 | /s/ Mark McDonnell | * Mark McDonnell, as Attorney-in-Fact for Steven Gillis | |
| Robert Nelsen | 9.4% | 4,120,053 | 0 | 4,120,053 | /s/ Mark McDonnell | * Mark McDonnell, as Attorney-in-Fact for Robert Nelsen |
CIK / CUSIP context first